Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 15/20 | 0.51 |
| ▸ | MTHFD1 | P11586 | 9/20 | 0.51 |
| ▸ | WDR5 | P61964 | 4/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20209037 | 0.88 | MTHFD2 (0.47) | MTHFD2MTHFD1WDR5 | |
| SCHEMBL21354135 | 0.84 | MTHFD2 (0.65) | MTHFD2MTHFD1ERN1 | |
| SCHEMBL21354117 | 0.80 | MTHFD2 (0.81) | MTHFD2MTHFD1WDR5 | |
| SCHEMBL24439672 | 0.80 | MTHFD2 (0.66) | MTHFD2MTHFD1WDR5 | |
| SCHEMBL29654976 | 0.80 | MTHFD2 (0.81) | MTHFD2MTHFD1WDR5 | |
| SCHEMBL20208614 | 0.80 | MTHFD1 (0.39) | MTHFD2MTHFD1WDR5ERN1 | |
| Hydrochloric Acid SCHEMBL21354118 | 0.79 | MTHFD1 (0.38) | MTHFD2MTHFD1WDR5ERN1 | |
| SCHEMBL21354141 | 0.78 | MTHFD2 (0.45) | MTHFD2MTHFD1ERN1 | |
| SCHEMBL24439860 | 0.78 | MTHFD2 (0.69) | MTHFD2MTHFD1WDR5 | |
| SCHEMBL21354132 | 0.77 | MTHFD2 (0.82) | MTHFD2MTHFD1WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3546463-B1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | DAIICHI SANKYO CO LTD (JP) | 2022-12-07 | — | — | EP | disclosed |
| US-10774087-B2 | Sulfonamide derivative having coumarin skeleton | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| EP-3546463-A1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | Daiichi Sankyo Co., Ltd. (JP) | 2019-10-02 | — | — | EP | disclosed |
| US-20190284198-A1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284198-A1 | SULFONAMIDE DERIVATIVE HAVING COUMARIN SKELETON | MTHFD1, MTHFD2, DHFR | MTHFD2 2/4885MTHFD1 1/4885WDR5 791/4885 |
| US-10774087-B2 | Sulfonamide derivative having coumarin skeleton | MTHFD1, MTHFD2, DHFR | MTHFD2 2/4885MTHFD1 1/4885WDR5 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.